CPC A61K 31/4706 (2013.01) [A61P 33/06 (2018.01); C07D 215/40 (2013.01); Y02A 50/30 (2018.01)] | 10 Claims |
1. A method of prevention of symptomatic P. falciparum malaria in a human subject, comprising:
a) administering to the human subject three loading doses of tafenoquine, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising tafenoquine, wherein each loading dose comprises about 200 mg of tafenoquine and is administered once a day for three days prior to potential exposure of the subject to P. falciparum;
b) administering to the human subject a maintenance dose of tafenoquine, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising tafenoquine once per week during potential exposure of the subject to P. falciparum, wherein each maintenance dose comprises about 200 mg of tafenoquine; and
c) administering to the human subject a post-exposure dose of tafenoquine, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising tafenoquine once seven days after the last maintenance dose, wherein said post-exposure dose comprises about 200 mg of tafenoquine;
wherein the first maintenance dose is administered seven days after the third loading dose;
wherein the administering of said a), b), and/or c) is with food; and
wherein the human subject is malaria-naïve and does not have a Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
|